ArticleWorld journal of surgical oncology2026
LncRNA LINC01579/miR-579-3p axis promotes gastric cancer progression via NOTCH1 pathway.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe function of long non-coding RNAs (lncRNAs) in gastric cancer (GC) has received increasing attention. This study aims to explore the role of LINC01579 in GC.
methodsOne hundred GC subjects were included. The abundance of LINC01579, miR-579-3p, and NOTCH1 signaling-related genes was measured in GC tissues and cell lines using qRT-PCR. Prognostic significance was evaluated through Kaplan-Meier estimator and Cox analysis. The interaction between LINC01579 and miR-579-3p was analyzed using Pearson correlation, bioinformatics prediction, and validated by dual-luciferase reporter assays. Cell proliferation was assessed using the CCK-8 assay, while apoptosis was evaluated by FITC Annexin V/PI staining followed by flow cytometry. Co-transfection experiments were performed to explore functional interactions.
resultsLINC01579 was elevated, whereas miR-579-3p was reduced in GC tissues and cell lines. Higher LINC01579 was associated with advanced pTNM stage, lymph node metastasis, and poor overall survival, identifying it as an independent prognostic factor. LINC01579 directly targeted miR-579-3p, with a significant negative correlation between their expression levels. Functionally, LINC01579 promoted tumor cell proliferation, inhibited apoptosis, and activated the NOTCH1 signaling (NOTCH1, DLL1, HES1), while miR-579-3p partially reversed these effects.
conclusionLINC01579 was a promising prognostic candidate in GC. These findings indicated that LINC01579/miR-579-3p facilitates GC progression through cell proliferation, apoptosis, and NOTCH1 signaling, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.